Linked Life Data

2013238

Source:http://linkedlifedata.com/resource/pubmed/id/2013238

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1991-5-14
pubmed:abstractText
In vitro antibacterial activity of the new penem FCE 22101 was tested against blood culture isolates from 1,374 consecutive patients in a major tertiary care referral center in Saudi Arabia. Many of the isolates were significantly more resistant to commonly used beta lactams. Of the 809 members of Enterobacteriaceae tested all but 14 isolates of Enterobacter were susceptible to FCE 22101 with an MIC range of 0.12-8.0 micrograms/ml. It inhibited all the 183 isolates of Staphylococcus aureus, both methicillin-sensitive and methicillin-resistant. Ninety percent of coagulase-negative staphylococci and enterococci were susceptible to this new penem. All isolates of Acinetobacter, CDC group VE-2 and Brucella melitensis from blood were inhibited by FCE 22101. However, it was ineffective against pseudomonads. Of the nine other beta lactam drugs tested for comparison, only imipenem was found to be more inhibitory, at lower MIC values, than FCE 22101.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0009-3157
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
15-22
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Antibacterial activity of FCE 22101 against relatively resistant blood culture isolates.
pubmed:affiliation
King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
pubmed:publicationType
Journal Article, Comparative Study